Pixium Vision executes the planned drawdown of the second tranche of its bond financing agreementadmin2019-09-11T17:32:21+02:00June 30th, 2017|
Pixium Vision advances in discussions with FDA for a feasibility study with its PRIMA system for Dry-AMDadmin2019-09-11T17:32:23+02:00June 13th, 2017|
Pixium Vision advances in review by the French health authority for eligibility of IRIS®II reimbursement under Forfait Innovationadmin2019-09-11T17:32:26+02:00May 24th, 2017|
Pixium Vision and research partners report progress in multiple areas with IRIS® and PRIMA during ARVO 2017 World Conferenceadmin2019-09-11T17:32:26+02:00May 3rd, 2017|
Pixium Vision makes available its 2016 Registration documentadmin2019-09-11T17:32:27+02:00April 27th, 2017|
Pixium Vision reports on March 31 2017 cash position and updates on development of its businessadmin2019-09-11T17:32:27+02:00April 25th, 2017|
Pixium Vision announces the planned drawdown of the first tranche of its bond financing agreementadmin2019-09-11T17:32:28+02:00March 28th, 2017|
Pixium Vision announces first implantation and activation of IRIS® II in Spainadmin2019-09-11T17:32:29+02:00February 16th, 2017|
Pixium Vision appoints Didier Laurens as Chief Financial Officeradmin2019-09-11T17:32:29+02:00February 15th, 2017|
Pixium Vision receives NUB innovation reimbursement Status-1 for 150 electrode IRIS®II bionic system in Germanyadmin2019-09-11T17:32:30+02:00February 14th, 2017|
Full year update on Pixium Vision’s liquidity agreement with Gilbert Dupontadmin2019-09-11T17:32:31+02:00January 17th, 2017|
